Lyell Immunopharma (LYEL)

• Market cap: $665M
• 1 day: 6.87%
• 5 days: 39.15%
• 1 month: 76.92%
• 3 months: 139.33%
• 6 months: 189.63%
• Year to date: 142.48%
• 1 year: 70.93%
• 5 years: -90.74%
• 10 years: -90.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300